Asembia’s AXS24 Summit
La démonstration de la valeur et l’optimisation de l’accès nécessitent un partenaire qui comprend la définition unique de la valeur de chaque intervenant et l’impact de ces définitions et besoins sur votre marque tout au long du cycle de vie du produit.
Syneos Health Value & Access can simplify the complex landscape with a team purpose-built to ensure that all aspects of value demonstration aren’t just interconnected – they’re orchestrated to be optimized, at every stage of your product’s lifecycle.
Meet with Us
Our team of experts will be on the floor at Asembia’s AXS24 Summit to show how we can help companies confidently navigate the shifting market landscape, create and communicate value and optimize access, including:
Optimizing Patient Support (HUB) Services: Improving the operational effectiveness and customer experience through a multi-disciplinary approach
Preparing for US Policy Changes: Future-proofing company and brand success in light of US policy shifts including the evolution of the Inflation Reduction Act
Focusing on Organized Customers: Optimizing collaborative partnerships between manufacturers and organized customers (IDNs/Systems) through real-world insights
Schedule a meeting to discuss your pressing access challenges.
Featured Session
Are Strategic Collaborations Part of Your IDN Strategy? A Panel with Syneos Health System Experts
May 1 | 3pm PT
Related Content:
Vous voulez en savoir plus? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
Capabilities
Cell & Gene Therapy Market Access Solutions
Optimizing Engagement with Integrated Health Systems and Organized Customers
Connaissances
BLOG: Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What’s Next
Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies
BLOG: What Can We Learn From ICER's New Value Framework
Syneos Health Podcast | Market Access for Weight Loss Drugs
MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts
BLOG: What ICER’s Draft Sickle Cell Disease Report Means for CGT Pricing
Syneos Health Podcast | Real Talk About the Inflation Reduction Act
